https://www.oncologynurseadvisor.com Tue, 27 Feb 2024 14:25:18 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/tepmetko-gets-traditional-approval-for-met-exon-14-skipping-nsclc/ Tue, 27 Feb 2024 14:15:00 +0000 https://www.oncologynurseadvisor.com/?p=116788 https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/obecabtagene-autoleucel-under-review-for-relapsed-refractory-b-cell-all/ Fri, 02 Feb 2024 15:20:00 +0000 https://www.empr.com/?p=214318 https://www.oncologynurseadvisor.com/home/cancer-types/hematologic-cancers/fda-safety-label-changes-required-for-bcma-cd19-directed-car-t-cell-therapies/ Fri, 26 Jan 2024 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=116185 https://www.oncologynurseadvisor.com/home/cancer-types/hematologic-cancers/jylamvo-an-fda-approved-oral-solution-formulation-of-methotrexate-now-available/ Wed, 27 Dec 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=115055 Jylamvo contains 2mg of methotrexate per mL and is packaged in bottles containing 60mL of oral solution.]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/bevacizumab-biosimilar-avzivi-receives-fda-approval/ Tue, 26 Dec 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=115136 The FDA has approved Avzivi (bevacizumab-tnjn), a biosimilar to Avastin (bevacizumab).]]> https://www.oncologynurseadvisor.com/home/cancer-types/prostate-cancer/akeega-an-oral-combo-therapy-for-brca-mutated-mcrpc-gets-fda-approval/ Wed, 23 Aug 2023 14:50:00 +0000 https://www.oncologynurseadvisor.com/?p=109875 The FDA has approved Akeega (niraparib and abiraterone acetate) to treat BRCA-mutated metastatic castration-resistant prostate cancer.]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/fda-grants-accelerated-approval-to-elrexfio-for-relapsed-refractory-multiple-myeloma/ Wed, 23 Aug 2023 14:40:00 +0000 https://www.empr.com/?p=202298 Elrexfio is expected to be available in the coming weeks. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/gavreto-granted-full-approval-for-ret-fusion-positive-nsclc/ Tue, 22 Aug 2023 14:50:00 +0000 https://www.empr.com/?p=202111 The FDA has granted full approval to Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive NSCLC. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/talvey-gets-accelerated-approval-for-difficult-to-treat-multiple-myeloma/ Tue, 22 Aug 2023 14:40:00 +0000 https://www.empr.com/?p=202121 The FDA has granted accelerated approval to Talvey (talquetamab) for the treatment of adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/keytruda-granted-full-approval-for-advanced-msi-h-or-dmmr-solid-tumors/ Wed, 05 Apr 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=106248 Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody.]]>